Limonin Is a Novel Hexokinase 2 Inhibitor That Suppresses Hepatic Stellate Cell Activation and Histone Lactylation
The FASEB Journal · 2026
DOI: 10.1096/fj.202504035r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Tian Lan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Histones, Hexokinase, Limonins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: | Medical and Health Research Project of Zhejiang Province (), Quzhou Municipal Science and Technology Bureau (), Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Hexokinase 2 (HK2) is a pivotal enzyme in glycolytic metabolism and plays a crucial role in the activation of hepatic stellate cells (HSCs). Despite its importance, specific inhibitors targeting HK2 are still lacking in clinical practice. In this study, we utilized a human protein microarray to identify a significant interaction between limonin (Lim) and HK2. Subsequent analyses confirmed that Lim effectively inhibits HK2 activity and the modification of histone lactylation. Moreover, Lim's systemic effects include the downregulation of gene expression associated with HSC activation, which is closely linked to its modulation of HK2 and histone lactylation. Additionally, Lim exhibits anti‐fibrotic properties, influencing the expression of genes involved in HSC activation and histone lactylation in vivo. These findings provide novel mechanistic insights into how Lim derivatives may mitigate hepatic fibrosis through the suppression of HK2 and targeted regulation of histone lactylation in activated HSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
- Department of Pharmacy, Quzhou Kecheng People's Hospital, Quzhou, China.
- Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
- Zhejiang Chinese Medical University Affiliated Four-Provinces Marginal Hospital of Traditional Chinese Medicine, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, China.
- Department of Infectious Diseases, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
ORCID-Profile: Si-Wei Wang
Förderung
- | Medical and Health Research Project of Zhejiang Province ()
- Quzhou Municipal Science and Technology Bureau ()
- Zhejiang Provincial Natural Science Foundation of China
- Medical and Health Research Project of Zhejiang Province
Zitieren
APA
Lan, T., Wang, C. C., Ying, J. J., Wang, W., Zeng, X. X., Mao, W. L., Lu, T., & Wang, S. W. (2026). Limonin Is a Novel Hexokinase 2 Inhibitor That Suppresses Hepatic Stellate Cell Activation and Histone Lactylation. The FASEB Journal. https://doi.org/10.1096/fj.202504035r
Vancouver
Lan T, Wang CC, Ying JJ, Wang W, Zeng XX, Mao WL, et al. Limonin Is a Novel Hexokinase 2 Inhibitor That Suppresses Hepatic Stellate Cell Activation and Histone Lactylation. The FASEB Journal. 2026. doi:10.1096/fj.202504035r
BibTeX
@article{Lan2026,
author = {Lan, Tian and Wang, Chen-Chen and Ying, Jun-Jie and Wang, Wen and Zeng, Xi-Xi and Mao, Wei-Li and Lu, Tao and Wang, Si-Wei},
title = {Limonin Is a Novel Hexokinase 2 Inhibitor That Suppresses Hepatic Stellate Cell Activation and Histone Lactylation},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202504035r}
}
EUVIMED